Natural History Study of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria of High-risk Hemolysis in China

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05125341

Enrollment

Registered

2021-11-18

Start date

2021-11-25

Completion date

2022-04-30

Last updated

2022-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paroxysmal Nocturnal Hemoglobinuria, Natural History Study

Brief summary

This is a single-center observational study conducted in adult patients with paroxysmal nocturnal hemoglobinuria of high-risk hemolysis. This observational study consists of two parts, one part is retrospective study which aims to collect medical chart data to calculate the mean change or mean incidence rates of LDH, hemoglobin, PNH-related symptoms and PNH-related events over 6 months. The other part is cross-sectional study to detect the total C5 level in PUMCH at the latest follow-up visit in eligible PNH patients with high-risk hemolysis, to show the difference between eligible PNH patients and healthy people and to explore the related clinical factor influencing high-level total C5 using logistic regression model.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

1. Meet the diagnostic criteria for paroxysmal nocturnal hemoglobinuria; 2. Age ≥ 18 years old; 3. PNH clone size of granulocytes or monocytes (CD59 or Flaer) ≥ 10%; 4. LDH≥1.5 ULN; 5. Accompanied by at least one PNH-related symptoms: fatigue, hemoglobinuria, abdominal pain, dyspnea, anemia symptoms, major adverse vascular events (including thrombosis), dysphagia, erectile dysfunction; 6. Transfusion-dependent PNH patients; 7. There are at least 6 months consecutive data of diagnosis and treatment after the data collection time point; 8. Patients agreed to participate in the study by signing informed consent or giving oral informed consent.

Exclusion criteria

1. Patients are under the treatment of the C1/C3/C5 complement inhibitors currently or in the past; 2. Patients have received bone marrow transplantation; 3. platelet count \<30\*10 9/L or absolute neutrophil count \<0.5\*10 9/L; 4. Patients have clinically significant heart, liver, or lung diseases, or have related medical history. 5. Patients have comorbidities of rheumatoid disease, HIV infection, active HBV infection, HCV infection and other diseases that affect the body's immune function; 6. Severe missing data in the records of diagnosis and treatment after the data collection time point; 7. Other patients who are not suitable to participate in the study.

Design outcomes

Primary

Measure	Time frame	Description
the mean change of LDH	6 months	the mean change of LDH over 6 months

Countries

China

Outcome results